ArticleJournal of thoracic disease2026

Selection bias and molecular blind spots: re-evaluating flumonertinib rechallenge in third-generation TKI-resistant non-small cell lung cancer.

Mengnan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.